FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361957787> ?p ?o ?g. }

• W4361957787 abstract "<div>AbstractPurpose:<p>Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomized clinical trials failed to show a significant survival benefit in molecularly unselected patients with advanced gastroesophageal adenocarcinoma treated with anti-EGFR agents.</p>Experimental Design:<p>We performed analyses on four cohorts: IRCC (570 patients), Foundation Medicine, Inc. (9,397 patients), COG (214 patients), and the Fondazione IRCCS Istituto Nazionale dei Tumori (206 patients). Preclinical trials were conducted in patient-derived xenografts (PDX).</p>Results:<p>The analysis of different gastroesophageal adenocarcinoma patient cohorts suggests that <i>EGFR</i> amplification drives aggressive behavior and poor prognosis. We also observed that EGFR inhibitors are active in patients with <i>EGFR</i> copy-number gain and that coamplification of other receptor tyrosine kinases or <i>KRAS</i> is associated with worse response. Preclinical trials performed on <i>EGFR</i>-amplified gastroesophageal adenocarcinoma PDX models revealed that the combination of an EGFR mAb and an EGFR tyrosine kinase inhibitor (TKI) was more effective than each monotherapy and resulted in a deeper and durable response. In a highly <i>EGFR-</i>amplified nonresponding PDX, where resistance to EGFR drugs was due to inactivation of the <i>TSC2</i> tumor suppressor, cotreatment with the mTOR inhibitor everolimus restored sensitivity to EGFR inhibition.</p>Conclusions:<p>This study underscores EGFR as a potential therapeutic target in gastric cancer and identifies the combination of an EGFR TKI and a mAb as an effective therapeutic approach. Finally, it recognizes mTOR pathway activation as a novel mechanism of primary resistance that can be overcome by the combination of EGFR and mTOR inhibitors.</p><p><i>See related commentary by Openshaw et al., p. 2964</i></p></div>" @default.
• W4361957787 created "2023-04-05" @default.
• W4361957787 creator A5001494473 @default.
• W4361957787 creator A5001675766 @default.
• W4361957787 creator A5001941833 @default.
• W4361957787 creator A5003232516 @default.
• W4361957787 creator A5004113834 @default.
• W4361957787 creator A5008503566 @default.
• W4361957787 creator A5012895580 @default.
• W4361957787 creator A5019891219 @default.
• W4361957787 creator A5029789134 @default.
• W4361957787 creator A5030218831 @default.
• W4361957787 creator A5031031537 @default.
• W4361957787 creator A5035120516 @default.
• W4361957787 creator A5041929329 @default.
• W4361957787 creator A5044033864 @default.
• W4361957787 creator A5045865889 @default.
• W4361957787 creator A5047888321 @default.
• W4361957787 creator A5050635377 @default.
• W4361957787 creator A5059339154 @default.
• W4361957787 creator A5059509038 @default.
• W4361957787 creator A5061054780 @default.
• W4361957787 creator A5062019987 @default.
• W4361957787 creator A5062176003 @default.
• W4361957787 creator A5064495942 @default.
• W4361957787 creator A5065261887 @default.
• W4361957787 creator A5067200921 @default.
• W4361957787 creator A5067402699 @default.
• W4361957787 creator A5067440696 @default.
• W4361957787 creator A5067964575 @default.
• W4361957787 creator A5070555185 @default.
• W4361957787 creator A5071393480 @default.
• W4361957787 creator A5073205869 @default.
• W4361957787 creator A5075464309 @default.
• W4361957787 creator A5079437223 @default.
• W4361957787 creator A5079727252 @default.
• W4361957787 creator A5080269874 @default.
• W4361957787 creator A5085703360 @default.
• W4361957787 creator A5088559019 @default.
• W4361957787 creator A5088809839 @default.
• W4361957787 creator A5089164502 @default.
• W4361957787 creator A5089475176 @default.
• W4361957787 creator A5090036776 @default.
• W4361957787 creator A5091555943 @default.
• W4361957787 date "2023-03-31" @default.
• W4361957787 modified "2023-10-17" @default.
• W4361957787 title "Data from Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas" @default.
• W4361957787 doi "https://doi.org/10.1158/1078-0432.c.6530756.v1" @default.
• W4361957787 hasPublicationYear "2023" @default.
• W4361957787 type Work @default.
• W4361957787 citedByCount "0" @default.
• W4361957787 crossrefType "posted-content" @default.
• W4361957787 hasAuthorship W4361957787A5001494473 @default.
• W4361957787 hasAuthorship W4361957787A5001675766 @default.
• W4361957787 hasAuthorship W4361957787A5001941833 @default.
• W4361957787 hasAuthorship W4361957787A5003232516 @default.
• W4361957787 hasAuthorship W4361957787A5004113834 @default.
• W4361957787 hasAuthorship W4361957787A5008503566 @default.
• W4361957787 hasAuthorship W4361957787A5012895580 @default.
• W4361957787 hasAuthorship W4361957787A5019891219 @default.
• W4361957787 hasAuthorship W4361957787A5029789134 @default.
• W4361957787 hasAuthorship W4361957787A5030218831 @default.
• W4361957787 hasAuthorship W4361957787A5031031537 @default.
• W4361957787 hasAuthorship W4361957787A5035120516 @default.
• W4361957787 hasAuthorship W4361957787A5041929329 @default.
• W4361957787 hasAuthorship W4361957787A5044033864 @default.
• W4361957787 hasAuthorship W4361957787A5045865889 @default.
• W4361957787 hasAuthorship W4361957787A5047888321 @default.
• W4361957787 hasAuthorship W4361957787A5050635377 @default.
• W4361957787 hasAuthorship W4361957787A5059339154 @default.
• W4361957787 hasAuthorship W4361957787A5059509038 @default.
• W4361957787 hasAuthorship W4361957787A5061054780 @default.
• W4361957787 hasAuthorship W4361957787A5062019987 @default.
• W4361957787 hasAuthorship W4361957787A5062176003 @default.
• W4361957787 hasAuthorship W4361957787A5064495942 @default.
• W4361957787 hasAuthorship W4361957787A5065261887 @default.
• W4361957787 hasAuthorship W4361957787A5067200921 @default.
• W4361957787 hasAuthorship W4361957787A5067402699 @default.
• W4361957787 hasAuthorship W4361957787A5067440696 @default.
• W4361957787 hasAuthorship W4361957787A5067964575 @default.
• W4361957787 hasAuthorship W4361957787A5070555185 @default.
• W4361957787 hasAuthorship W4361957787A5071393480 @default.
• W4361957787 hasAuthorship W4361957787A5073205869 @default.
• W4361957787 hasAuthorship W4361957787A5075464309 @default.
• W4361957787 hasAuthorship W4361957787A5079437223 @default.
• W4361957787 hasAuthorship W4361957787A5079727252 @default.
• W4361957787 hasAuthorship W4361957787A5080269874 @default.
• W4361957787 hasAuthorship W4361957787A5085703360 @default.
• W4361957787 hasAuthorship W4361957787A5088559019 @default.
• W4361957787 hasAuthorship W4361957787A5088809839 @default.
• W4361957787 hasAuthorship W4361957787A5089164502 @default.
• W4361957787 hasAuthorship W4361957787A5089475176 @default.
• W4361957787 hasAuthorship W4361957787A5090036776 @default.
• W4361957787 hasAuthorship W4361957787A5091555943 @default.
• W4361957787 hasBestOaLocation W43619577872 @default.
• W4361957787 hasConcept C121608353 @default.
• W4361957787 hasConcept C126322002 @default.
• W4361957787 hasConcept C143998085 @default.
• W4361957787 hasConcept C170493617 @default.
• W4361957787 hasConcept C2777506169 @default.

• next